Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 28;8(1):5349.
doi: 10.1038/s41598-018-23703-w.

Attenuated Notch signaling in schizophrenia and bipolar disorder

Affiliations

Attenuated Notch signaling in schizophrenia and bipolar disorder

Eva Z Hoseth et al. Sci Rep. .

Abstract

The Notch signaling pathway plays a crucial role in neurodevelopment and in adult brain homeostasis. We aimed to further investigate Notch pathway activity in bipolar disorder (BD) and schizophrenia (SCZ) by conducting a pathway analysis. We measured plasma levels of Notch ligands (DLL1 and DLK1) using enzyme immunoassays in a large sample of patients (SCZ n = 551, BD n = 246) and healthy controls (HC n = 639). We also determined Notch pathway related gene expression levels by microarray analyses from whole blood in a subsample (SCZ n = 338, BD n = 241 and HC n = 263). We found significantly elevated Notch ligand levels in plasma in both SCZ and BD compared to HC. Significant gene expression findings included increased levels of RFNG and KAT2B (p < 0.001), and decreased levels of PSEN1 and CREBBP in both patient groups (p < 0.001). RBPJ was significantly lower in SCZ vs HC (p < 0.001), and patients using lithium had higher levels of RBPJ (p < 0.001). We provide evidence of altered Notch signaling in both SCZ and BD compared to HC, and suggest that Notch signaling pathway may be disturbed in these disorders. Lithium may ameliorate aberrant Notch signaling. We propose that drugs targeting Notch pathway could be relevant in the treatment of psychotic disorders.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Summary of significant and nominally significant findings in Notch pathway mRNA expression between the schizophrenia and the healthy control group after controlling for age, gender and Bmal1. Results are given as p-values, adjusted for multiple testing, where significant results are indicated in red/dark blue (for increased/decreased mRNA expression) and nominally significant results (0.001 < p < 0.05) are shown as pink/light blue (for increased/decreased mRNA expression). Non-significant results are depicted as boxes with white background. The figure is based on the Notch signaling pathway in the KEGG database (hsa04330, version date 5/9/17). Hey1 is included by the authors due to its known role as a target gene for Notch signaling.
Figure 2
Figure 2
Summary of significant and nominally significant findings in Notch pathway mRNA expression between the bipolar disorder and the healthy control group after controlling for age, gender and Bmal1. Results are given as p-values, adjusted for multiple testing, where significant results are indicated in red/dark blue (for increased/decreased mRNA expression) and nominally significant results (0.001 < p < 0.05) are shown as pink/light blue (for increased/decreased mRNA expression). Non-significant results are depicted as boxes with white background. The figure is based on the Notch signaling pathway in the KEGG database (hsa04330, version date 5/9/17). Hey1 is included by the authors due to its known role as a target gene for Notch signaling.

References

    1. Ferrari AJ, et al. The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013. Bipolar disorders. 2016;18:440–450. doi: 10.1111/bdi.12423. - DOI - PubMed
    1. Chong HY, et al. Global economic burden of schizophrenia: a systematic review. Neuropsychiatric disease and treatment. 2016;12:357–373. - PMC - PubMed
    1. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Archives of general psychiatry. 1987;44:660–669. doi: 10.1001/archpsyc.1987.01800190080012. - DOI - PubMed
    1. O’Shea KS, McInnis MG. Neurodevelopmental origins of bipolar disorder: iPSC models. Molecular and cellular neurosciences. 2016;73:63–83. doi: 10.1016/j.mcn.2015.11.006. - DOI - PubMed
    1. Pino O, et al. Neurodevelopment or neurodegeneration: review of theories of schizophrenia. Actas espanolas de psiquiatria. 2014;42:185–195. - PubMed

Publication types

Substances